Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
International Journal of Cancer|February 28, 2015
Association of PSCA rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer diseaseMaría Asunción García-González, Luis Bujanda, Enrique Quintero, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2025
Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registryCarlos López-López, Eva Martínez de Castro, Ana Fernández Montes, et al.Mutagenesis|September 7, 2012
Relevance of GSTM1, GSTT1, and GSTP1 gene polymorphisms to gastric cancer susceptibility and phenotypeM Asunción García-González, Enrique Quintero, Luis Bujanda, et al.Future Oncology (London, England)|March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagusYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.Palliative Care and Social Practice|February 14, 2024
Improving shared decision-making about cancer treatment through design-based data-driven decision-support tools and redesigning care paths: an overview of the 4D PICTURE projectJudith A C Rietjens, Ingeborg Griffioen, Jorge Sierra-Pérez, et al.Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyLin Shen, Ken Kato, Sung-Bae Kim, et al.Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.European Journal of Cancer (Oxford, England : 1990)|February 22, 2017
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative GroupAntonio Irigoyen, Javier Gallego, Carmen Guillén Ponce, et al.BMJ (Clinical Research Ed.)|May 28, 2024
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trialMiao-Zhen Qiu, Do-Youn Oh, Ken Kato, et al.Pageof 6